No. 10 Medical Innovation for 2020: Drugs for Heart Failure with Preserved Ejection Fraction

SGLT2 inhibitors already show heart benefits in diabetes patients

For patients with heart failure with preserved ejection fraction (HFpEF), current treatments address only accompanying conditions and symptoms. Therapy commonly involves treating high blood pressure and coronary artery disease, and encouraging weight loss and smoking cessation.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

However, in 2020 we may see FDA approval of a class of medications, SGLT2 inhibitors, for the treatment of HFpEF. These medications already have shown reduced risk of cardiovascular death and heart failure hospitalization in patients with type 2 diabetes. Research is ongoing — yet promising — in HFpEF patients without diabetes.

In this video, learn more about why SGLT2 inhibitors are one of Cleveland Clinic’s Top 10 Medical Innovations for 2020.


Related Articles

23-CCC-4375920 Zipline drone delivery 650×450
Delivering Drugs via Drone

Cleveland Clinic will offer rapid, pinpoint airborne transport of medications and other medical items

SEM_Knipfer_3797162_Mentor Hospital Community Grand Opening_06-2
How Cleveland Clinic Is Greening Its Operating Rooms

Dedicated committee and surgical fellowship strive for sustainability, energy efficiency, waste reduction

Top 10 Medical Innovations for 2022 Unveiled

Next-generation mRNA vaccines are among the advancements likely to change healthcare this year

Why Lead Safety Has Become Cleveland Clinic’s Top Priority for Community Health

$50 million pledge will help remove sources of lead exposure from Cleveland homes

Nurse conducts safety check on medications in hospital hallway
10 Leadership Mindsets for High Reliability Organizations

How to empower caregivers and engage patients in patient safety

10 Things Not To Miss at MIS2020

Summit to cap off with Annual Top 10 Medical Innovations

Thomas Mroz, MD, Named Chair of the Orthopaedic & Rheumatologic Institute

The spine surgeon will oversee more than 125 staff physicians in his new role

James Merlino, MD
James Merlino, MD, Named Inaugural Chief Clinical Transformation Officer

Merlino rejoins Cleveland Clinic to help execute bold strategic vision